Status of liquid profiling in precision oncology – the need for integrative diagnostics for successful implementation into standard care
Author:
Froelich Matthias F.1ORCID, Schoenberg Stefan O.1, Neumaier Michael2, Haselmann Verena2ORCID
Affiliation:
1. Department of Radiology and Nuclear Medicine , Medical Faculty Mannheim of the University of Heidelberg, University Hospital Mannheim , Mannheim , Germany 2. Institute of Clinical Chemistry , Medical Faculty Mannheim of the University of Heidelberg, University Hospital Mannheim , Mannheim , Germany
Abstract
Abstract
The liquid profiling approach is currently at the threshold of translation from research application in various clinical trials to introduction into the management of cancer patients in the context of clinical care. Routine application has focused primarily on the analysis of single blood-based biomarkers for companion diagnostics. However, liquid profiling promises much broader diagnostic potential, which is discussed and illustrated in this manuscript through several case reports. These clinical cases range from identification of druggable targets to the detection of subclonal resistance mechanisms. In addition, liquid profiling can be used in clinical practice to identify complex molecular patterns or as a personalized tumor marker for patient-specific monitoring of response to treatment. These examples highlight both the value and limitations of liquid profiling in various clinical settings, which could be overcome by an integrative diagnostic approach with imaging techniques. The complementary advantages of both diagnostics approaches will allow combining high sensitivity with genetic tumor profiling and topologic assignment. Therefore, we advocate interdisciplinary integrated collaboration between laboratory and imaging experts to unravel the potentials of precision diagnostics in cancer care.
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,Discrete Mathematics and Combinatorics
Reference39 articles.
1. Mandel, P, Metais, P. Nuclear acids in human blood plasma. C R Seances Soc Biol Fil 1948;142:241–3. 2. Sorenson, GD, Pribish, DM, Valone, FH, Memoli, VA, Bzik, DJ, Yao, SL. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev 1994;3:67–71. 3. Vasioukhin, V, Anker, P, Maurice, P, Lyautey, J, Lederrey, C, Stroun, M. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol 1994;86:774–9. https://doi.org/10.1111/j.1365-2141.1994.tb04828.x. 4. Pantel, K, Alix-Panabieres, C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 2010;16:398–406. https://doi.org/10.1016/j.molmed.2010.07.001. 5. Tie, J, Wang, Y, Tomasetti, C, Li, L, Springer, S, Kinde, I, et al.. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016;8:346ra92. https://doi.org/10.1126/scitranslmed.aaf6219.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|